We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits
Read MoreHide Full Article
Select Medical Holdings Corporation (SEM - Free Report) recently provided estimates for some crucial metrics for the year 2021. It plans to report fourth-quarter and full-year 2021 results on Feb 24, after the closing bell. Let’s see how the company fared in 2021 and which way estimates are headed.
Operational Update
SEM estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectation of $6.05-$6.15 billion. This indicates significant growth from the 2020 reported figure of $5.5 billion.
Yet, Select Medical’s increasing costs are eating into profits. Its critical illness recovery hospital segment witnessed a greater-than-expected usage of agency clinical staff in the fourth quarter. This might have increased costs for agency in the hospitals. Higher labor costs might have affected the company’s profits.
Adjusted EBITDA for 2021 is now estimated at $947 million, down from the previous forecast between $980 million and $1 billion. Nevertheless, this indicates an increase from the 2020 reading of $800.6 million.
Earnings for 2021 are expected within $2.90-$2.92 per share.
Q4 Estimates
The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 42 cents per share, indicating a decline of 26.3% from the year-ago figure. The estimate has been unchanged over the past week. Revenues for the fourth quarter are estimated at $1.5 billion, signaling a 3.7% increase from the year-ago period.
Select Medical boasts an impressive earnings surprise history. The company beat earnings estimates in each of the last four quarters, with the average being 69.2%. This is depicted in the graph below.
Select Medical Holdings Corporation Price and EPS Surprise
Globus Medicaldevelops healthcare solutions for patients with musculoskeletal disorders. GMED also provides products for orthopedic trauma treatments. The medical device company’s bottom line for 2021 is expected to jump 40.3% from the year-ago figure. Audubon, PA-based Globus Medical has witnessed one upward estimate revision in the past 60 days and no movement in the opposite direction. Globus Medical beat earnings estimates in each of the last four quarters, with the average being 21.4%.
Apyx Medical is a manufacturer of medical devices for cosmetic and surgical markets around the world. Based in Clearwater, FL, APYX’s bottom line for 2021 is expected to rise 17.5% year over year. It has witnessed one upward estimate revision in the past 60 days and no movement in the opposite direction. Apyx Medical beat earnings estimates thrice in the last four quarters and met once, with the average surprise being 25.9%.
Neogen develops products for food and animal safety all over the world. Based in Lansing, MI, the diagnostic and research company’s bottom line for the current year is expected to rise 15.8% year over year. Neogen is well poised to gain from its extensive global foothold and diverse product mix. The company’s long-term growth strategy is impressive.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits
Select Medical Holdings Corporation (SEM - Free Report) recently provided estimates for some crucial metrics for the year 2021. It plans to report fourth-quarter and full-year 2021 results on Feb 24, after the closing bell. Let’s see how the company fared in 2021 and which way estimates are headed.
Operational Update
SEM estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectation of $6.05-$6.15 billion. This indicates significant growth from the 2020 reported figure of $5.5 billion.
Yet, Select Medical’s increasing costs are eating into profits. Its critical illness recovery hospital segment witnessed a greater-than-expected usage of agency clinical staff in the fourth quarter. This might have increased costs for agency in the hospitals. Higher labor costs might have affected the company’s profits.
Adjusted EBITDA for 2021 is now estimated at $947 million, down from the previous forecast between $980 million and $1 billion. Nevertheless, this indicates an increase from the 2020 reading of $800.6 million.
Earnings for 2021 are expected within $2.90-$2.92 per share.
Q4 Estimates
The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 42 cents per share, indicating a decline of 26.3% from the year-ago figure. The estimate has been unchanged over the past week. Revenues for the fourth quarter are estimated at $1.5 billion, signaling a 3.7% increase from the year-ago period.
Select Medical boasts an impressive earnings surprise history. The company beat earnings estimates in each of the last four quarters, with the average being 69.2%. This is depicted in the graph below.
Select Medical Holdings Corporation Price and EPS Surprise
Select Medical Holdings Corporation price-eps-surprise | Select Medical Holdings Corporation Quote
Zacks Rank & Key Picks
Select Medical currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical space include Globus Medical, Inc. (GMED - Free Report) , Apyx Medical Corporation (APYX - Free Report) and Neogen Corporation (NEOG - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Globus Medicaldevelops healthcare solutions for patients with musculoskeletal disorders. GMED also provides products for orthopedic trauma treatments. The medical device company’s bottom line for 2021 is expected to jump 40.3% from the year-ago figure. Audubon, PA-based Globus Medical has witnessed one upward estimate revision in the past 60 days and no movement in the opposite direction. Globus Medical beat earnings estimates in each of the last four quarters, with the average being 21.4%.
Apyx Medical is a manufacturer of medical devices for cosmetic and surgical markets around the world. Based in Clearwater, FL, APYX’s bottom line for 2021 is expected to rise 17.5% year over year. It has witnessed one upward estimate revision in the past 60 days and no movement in the opposite direction. Apyx Medical beat earnings estimates thrice in the last four quarters and met once, with the average surprise being 25.9%.
Neogen develops products for food and animal safety all over the world. Based in Lansing, MI, the diagnostic and research company’s bottom line for the current year is expected to rise 15.8% year over year. Neogen is well poised to gain from its extensive global foothold and diverse product mix. The company’s long-term growth strategy is impressive.